Market closedNon-fractional
Voyager Therapeutics/VYGR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Voyager Therapeutics
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Ticker
VYGR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lexington, United States
Employees
162
Website
www.voyagertherapeutics.com
VYGR Metrics
BasicAdvanced
$500M
Market cap
-
P/E ratio
-$0.06
EPS
1.04
Beta
-
Dividend rate
Price and volume
Market cap
$500M
Beta
1.04
Financial strength
Current ratio
5.639
Quick ratio
5.555
Long term debt to equity
12.319
Total debt to equity
14.062
Management effectiveness
Return on assets (TTM)
-2.65%
Return on equity (TTM)
-1.09%
Valuation
Price to revenue (TTM)
3.639
Price to book
1.48
Price to tangible book (TTM)
1.48
Price to free cash flow (TTM)
52.622
Growth
Revenue change (TTM)
-37.58%
Earnings per share change (TTM)
-102.57%
3-year revenue growth (CAGR)
-9.30%
3-year earnings per share growth (CAGR)
-60.45%
What the Analysts think about VYGR
Analyst Ratings
Majority rating from 10 analysts.
VYGR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-78.33%
Net income
-$11M
-120.07%
Profit margin
-57.94%
-192.63%
VYGR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.59
$1.25
-$0.20
-
Expected
-$0.57
-$0.58
-$0.29
-$0.44
-$0.41
Surprise
-10.30%
1.50%
-533.17%
-54.55%
-
VYGR News
AllArticlesVideos
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 days ago
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Voyager Therapeutics stock?
Voyager Therapeutics (VYGR) has a market cap of $500M as of July 27, 2024.
What is the P/E ratio for Voyager Therapeutics stock?
The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 0 as of July 27, 2024.
Does Voyager Therapeutics stock pay dividends?
No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Voyager Therapeutics dividend payment date?
Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.
What is the beta indicator for Voyager Therapeutics?
Voyager Therapeutics (VYGR) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Voyager Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.